NM attorney general and two manufacturers cap diabetes drug costs in settlements
A pharmacy manager retrieves a bottle of antibiotics. (Photo by)
Under settlement agreements reached earlier this year and announced by New Mexico Attorney General Raúl Torrez on Wednesday, two insulin manufacturers have committed to make the diabetes treatment cheaper for New Mexicans.
'These are huge wins for New Mexicans who have struggled with the outrageous cost of insulin,' Torrez said in a statement. 'These agreements will help people stop rationing medication, avoid financial hardship, and focus on staying healthy. We are holding drug manufacturers accountable and making access to life-saving treatment more equitable.'
New Mexico Department of Justice spokesperson Lauren Rodriguez told Source NM that the agreements provide insured patients who might have a high deductible or copay the option to pay cash instead of using their insurance, and to pay no more than $35 for a monthly supply of insulin, Rodriguez said.
The New Mexico state law enacted in 2020 that caps insulin costs at $25 remains in full force and is not preempted or replaced by the new settlements, Rodriguez said.
Instead, the agreements are 'additive protections mainly aimed at helping cash-paying and uninsured patients, while deferring to state law when it offers better pricing,' she said.
As many as 207,600 adults in New Mexico, or approximately 11% of the state's adult population, have diabetes, according to the American Diabetes Association.
Without the caps, patients in other states could pay $150 per month or more, especially if they require multiple variations of the drug, Stateline reports.
More states are doing what they can to cap insulin costs
High out-of-pocket costs have historically forced many patients to choose between buying insulin and meeting other basic needs, NMDOJ said in a news release. The settlements result from the agency's independent investigations into insulin pricing practices, NMDOJ said.
The state's agreement with Sanofi-Aventis U.S. LLC, signed on April 18, requires the company to maintain its Insulins ValYou Savings Program, which allows patients who pay out-of-pocket to receive a month's supply for $35.
The Sanofi settlement also requires it to maintain its Patient Connection Program, which allows uninsured patients who aren't eligible for Medicaid and whose annual household income is at or below 400% of the federal poverty line to receive insulin for free.
Under the settlement, Sanofi must also provide patients live phone and translation support in Spanish, Hmong, Somali and Mandarin Chinese; and participating pharmacies will receive training to help patients enroll in affordability programs.
The settlement with Novo Nordisk Inc., signed on May 19, requires the company to maintain its MyInsulinRX Program, which offers diabetes patients the option to pay $35 or less for a monthly prescription. Under the agreement, Novo Nordisk must also continue its Patient Assistance Program, which offers insulin for free.
The settlement also requires Novo Nordisk to notify pharmacies about available discounts at the point of sale, help patients enroll on the spot and offer live phone and website chat support in Spanish.
Reporter Danielle Prokop contributed reporting to this story.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
11 hours ago
- Business Upturn
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' Grizzly stated that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, On this news, GeneDx's stock fell $4.84 per share, or 6.7%, to close at $67.18 per share on February 5, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Wall Street Journal
11 hours ago
- Wall Street Journal
Trump's ‘Big, Beautiful' Bill Gets Slimmed Down in Senate
WASHINGTON—President Trump's 'big, beautiful' bill is getting smaller just as Republicans head into a crucial week, after the Senate's rules arbiter decided several controversial provisions don't qualify for the special procedure the GOP is using to bypass Democratic opposition. The tax-and-spending megabill centers on extending Trump's 2017 tax cuts, delivering on the spirit of his campaign promises to eliminate taxes on tips and overtime, and providing big lump sums of money for border security and defense. Those new costs are partially offset by spending cuts, in particular to Medicaid.
Business Upturn
16 hours ago
- Business Upturn
ELV FRAUD ALERT: Elevance Health, Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 11 Legal Deadline (NYSE:ELV)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al. , No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility. During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid. As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024. The Stock Declines as the Truth is Revealed On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024. Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024. Click here if you suffered losses: What Can You Do? If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
